[{"orgOrder":0,"company":"PhaseBio Pharmaceuticals","sponsor":"SFJ Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"PB2452","moa":"P2Y12 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"PhaseBio Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.12,"dosageForm":"","sponsorNew":"PhaseBio Pharmaceuticals \/ SFJ Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"PhaseBio Pharmaceuticals \/ SFJ Pharmaceuticals"},{"orgOrder":0,"company":"Inotrem","sponsor":"Roche Diagnostics GmbH","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Nangibotide","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Inotrem \/ Roche Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Roche Diagnostics"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"LB1148","moa":"Serine protease","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"NTX-001","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Neuraptive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"NTX-001","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Neuraptive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Galecto","sponsor":"Pharmakea therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"DENMARK","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"PAT-1251","moa":"LOXL2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Galecto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Galecto \/ PharmAkea","highestDevelopmentStatusID":"8","companyTruncated":"Galecto \/ PharmAkea"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Revance Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Icahn School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Icahn School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Icahn School of Medicine"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Elezanumab","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution For Infusion; Intravenous","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Rediscovery Life Sciences","sponsor":"REX Health Ventures","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2020","type":"Series B Financing","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Rediscovery Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rediscovery Life Sciences \/ REX Health Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Rediscovery Life Sciences \/ REX Health Ventures"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"NTX-001","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical","sponsorNew":"Neuraptive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"PF-04457845","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0.40999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.40999999999999998,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"SpringWorks Therapeutics \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Oxeia Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Human Ghrelin","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oxeia Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Oxeia Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oxeia Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"LSALT peptide","moa":"DPEP1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Not Applicable"},{"orgOrder":0,"company":"Vapogenix","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Sevoflurane","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Vapogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Vapogenix \/ National Institute of Arthritis and Musculoskeletal and Skin Diseases","highestDevelopmentStatusID":"8","companyTruncated":"Vapogenix \/ National Institute of Arthritis and Musculoskeletal and Skin Diseases"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Bromelain enriched proteolytic enzymes","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Nezulcitinib","moa":"JAK","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Theravance Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ME3183","moa":"PDE4","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Meiji Seika Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Meiji Seika Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Adrenomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Adrecizumab","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Adrenomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adrenomed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adrenomed \/ Not Applicable"},{"orgOrder":0,"company":"SanBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Vandefitemcel","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"SanBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"SanBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"SanBio \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ME3183","moa":"PDE4","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Meiji Seika Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Meiji Seika Pharma \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AMT-101","moa":"IL-10","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Not Applicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Series A Financing","leadProduct":"Iron Sucrose","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Renibus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"MediWound \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ Not Applicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"MRM Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"MH002","moa":"Microbiome","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MRM Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MRM Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MRM Health \/ Not Applicable"},{"orgOrder":0,"company":"Oxeia Biopharmaceuticals","sponsor":"University of Kansas Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Human Ghrelin","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Oxeia Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Oxeia Biopharmaceuticals \/ University of Kansas Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Oxeia Biopharmaceuticals \/ University of Kansas Medical Center"},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2022","type":"Private Placement","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"MediWound \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Bromelain Enriched Proteolytic Enzyme","moa":"Peptide hydrolase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.029999999999999999,"dosageForm":"Gel","sponsorNew":"MediWound \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AMT-101","moa":"IL-10","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Not Applicable"},{"orgOrder":0,"company":"ChemomAb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CM-101","moa":"CCL24","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"ChemomAb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ChemomAb \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ChemomAb \/ Not Applicable"},{"orgOrder":0,"company":"Ophirex","sponsor":"AXA IM Prime Impact Master Fund","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2023","type":"Series B Financing","leadProduct":"Varespladib Methyl","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Ophirex","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Ophirex \/ AXA IM Prime Impact Master Fund","highestDevelopmentStatusID":"8","companyTruncated":"Ophirex \/ AXA IM Prime Impact Master Fund"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Bromelain","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.029999999999999999,"dosageForm":"Patch","sponsorNew":"MediWound \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"MediWound","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Bromelain","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"MediWound","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.029999999999999999,"dosageForm":"Patch","sponsorNew":"MediWound \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"MediWound \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"AMT-101","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Not Applicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Human Acellular Vessel","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Humacyte \/ Not Applicable"},{"orgOrder":0,"company":"Athersys","sponsor":"The University of Texas Health Science Center at Houston","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Invimestrocel","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Athersys","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Athersys \/ The University of Texas Health Science Center at Houston","highestDevelopmentStatusID":"8","companyTruncated":"Athersys \/ The University of Texas Health Science Center at Houston"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Renibus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Palisade Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tranexamic Acid","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Palisade Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"Palisade Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palisade Bio \/ Not Applicable"},{"orgOrder":0,"company":"Renibus Therapeutics","sponsor":"Juniper Point","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Series B Financing","leadProduct":"Iron Sucrose","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Renibus Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"Renibus Therapeutics \/ Juniper Point","highestDevelopmentStatusID":"8","companyTruncated":"Renibus Therapeutics \/ Juniper Point"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"NTX-001","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Neuraptive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"NTX-001","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Neuraptive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neuraptive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"NTX-001","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Neuraptive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Solution","sponsorNew":"Neuraptive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuraptive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Ampakine","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"RespireRx Pharmaceuticals \/ Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ Department of Defense"}]
Find Drugs for Trauma (Emergency, Injury, Surgery) in Phase II Clinical Development
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
